Revistar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Revistar

What is Revistar? (Flucloxacillin)

Property Description
Active ingredient Flucloxacillin (typically as Sodium salt)
Form Capsules, Oral Suspension, Powder for Injection
Pharmacological class beta-Lactam Penicillin Antibiotic
General purpose Elimination of susceptible bacterial infections
Origin Semisynthetic

What Type of Medicine is Revistar and What is it Made Of?

Revistar is a prescription-only medicine (POM) whose active ingredient is Flucloxacillin, classified within the semisynthetic beta-lactam antibiotic family. This positions it among the penicillins, a class widely recognized in clinical practice for treating microbial infections.

The composition relies on the INN substance, Flucloxacillin Sodium, a chemically modified compound. This preparation is a single active ingredient product intended for systemic use. Flucloxacillin is used to treat infections caused by susceptible organisms, such as those affecting the skin and soft tissue.


How is Flucloxacillin Different from Other Penicillins?

Flucloxacillin is classified as a penicillinase-resistant penicillin, a crucial structural feature that allows it to resist destructive bacterial defenses.

This distinction arises from a modification that grants it hydrolysis resistance to beta-lactamase (penicillinase) enzymes produced by certain bacteria. This capability secures the drug's functional integrity in clinical scenarios where standard penicillins would be deactivated. Flucloxacillin is primarily active against specific Gram-positive cocci like staphylococci and streptococci.


In What Forms is Revistar Available, and What is Its General Purpose?

Revistar is typically supplied in multiple identity-level dosage forms, including capsules and an oral suspension for administration by mouth, as well as a powder for solution for injection for parenteral routes.

The availability of these forms ensures flexible and effective systemic delivery. The overarching general therapeutic purpose of Revistar is to act as a bactericidal agent, leading to the elimination of susceptible bacterial infections within the body.

Regulatory References

  1. Flucloxacillin in WHO eEML
  2. Flucloxacillin Drug Record - LiverTox
  3. National Library of Medicine - Flucloxacillin
  4. Flucloxacillin Sodium Monohydrate (0668) - European Pharmacopoeia

What side effects are possible with Revistar?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety profile of Revistar, strictly based on regulatory documents from government health authorities worldwide (such as the FDA, EMA, Health Canada, or others).

Based on a review of accessible governmental regulatory databases, there is no publicly available official safety documentation for a drug named Revistar. Therefore, the essential elements that comprise a complete regulatory safety profile are not established in official records.


Safety Profile Component Regulatory Status
Adverse Reaction Scope Undocumented (No classification by frequency or System-Organ-Class)
Serious Adverse Reactions Undocumented (No official events classified as Serious Adverse Reactions)
Population Safety Notes Undocumented (No specific statements regarding special populations)
Safety Restrictions Undocumented (No formal restrictions or limitations defined in labels)

Regulatory Safety Summary

The absence of specific regulatory safety data means that the official categorization of side effects and associated risks for Revistar cannot be reported. Government regulations require a full submission and review process to define the frequency of adverse reactions, list serious risks, and determine safety limitations before a drug’s risk profile can be officially communicated. The lack of documented data prevents an authorized, fact-based understanding of the medicine’s regulatory risk profile. For any medical product, the risks, safety classifications, and adverse reactions are formally established through a rigorous regulatory process.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation on Revistar (Flucloxacillin) overdose describes specific clinical and systemic manifestations and mandates immediate emergency action.

Documented Overdose Manifestations

Overdose exposure is typically associated with gastrointestinal disturbances, including nausea, vomiting, and diarrhoea. With high parenteral doses, neurotoxicity and convulsions are documented manifestations, particularly in patients with impaired renal function. Haematologic changes such as blood disorders and metabolic disturbances, including electrolyte imbalance and potentially life-threatening Hypokalaemia (low potassium levels), have been associated with high-dose therapy.

Severe Outcomes and Population Risks

The regulatory profile highlights the risk of severe neurological disorders and states that high-dose use may precipitate serious outcomes. Newborns receiving high parenteral doses are specifically noted to be at risk of kernicterus. Furthermore, patients with pre-existing hepatic dysfunction or those over 50 years of age are documented as being at an increased risk of severe hepatic reactions following exposure.

Required Emergency Action

In the event of a suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. This action is required even if there are no immediate signs of discomfort. Management of the overdose is officially defined as symptomatic and supportive, and specific monitoring, such as the regular measurement of potassium levels, is recommended during high-dose exposure. No specific antidote is known.

Therapeutic Uses of Revistar

What Revistar Treats: Main Uses and Benefits

Revistar (Flucloxacillin) is a specialized antibiotic applied in addressing bacterial infections that are resistant to some standard penicillin treatments. Its usage is commonly used to help with the resolution of acute inflammation, the containment of bacterial spread, and the easing of localized and systemic discomfort driven by the infection.

The medication is generally used to help treat a variety of infections.


Therapeutic Scope and Benefits

Revistar is commonly used in conditions characterized by periods of heightened symptoms related to inflammatory or irritative states in the skin and soft tissues. It helps address symptom clusters that may become intense or disruptive, specifically the pronounced redness, swelling, heat, and localized pain seen in conditions such as cellulitis, impetigo, and localized abscesses.

The medicine is considered relevant in contexts involving heightened systemic burden, being applied in conditions presenting with systemic or localized discomfort, such as deep-seated osteomyelitis, endocarditis, and septicemia. This provides supportive relief needed to ease the impact of systemic symptoms like high fever and overall malaise.


“This medication is considered relevant in managing the acute phases of infection where severe inflammation and tissue involvement are present.”

Quick Fact: Relief for Acute Inflammation
Revistar is applied across domains where additional symptomatic support is needed to reduce the intensity of redness, swelling, and localized pain associated with susceptible bacterial infections.

Eligibility and Restrictions for Use

Revistar (Flucloxacillin) is an antibiotic prescribed for a range of bacterial infections, including those affecting the skin, soft tissues, and respiratory tract. It is effective against certain Gram-positive bacteria, particularly those that produce penicillinase.

Who Can Use Revistar

  • Adults and Children: It is used in all age groups, with dosage adjusted based on body weight for children.
  • Specific Infections: Indicated for conditions such as cellulitis, boils, infected wounds, pneumonia, tonsillitis, endocarditis, and osteomyelitis, among others.

Who Cannot Use Revistar

Revistar is contraindicated and must not be used in individuals with a known hypersensitivity or severe allergic reaction to penicillins or any other ingredient in the formulation. As an isoxazolyl penicillin, patients with an allergy to one type of penicillin may be sensitive to others.

Use with caution and under close medical supervision is necessary for patients with:

  • A history or evidence of hepatic (liver) dysfunction.
  • Severe renal (kidney) failure, as dosage adjustment may be required to prevent neurotoxicity.
  • A general allergic predisposition or diathesis.

Use in pregnancy and breastfeeding should only occur if the potential benefit outweighs the potential risk, as determined by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Revistar (Flucloxacillin) documents several clinically relevant interaction patterns with co-administered medicines and products.


Pharmacokinetic and Metabolic Interactions

Flucloxacillin is officially noted as a weak inducer of the CYP3A4 enzyme. This induction mechanism may lead to subtherapeutic plasma concentrations and potential loss of effectiveness for sensitive CYP3A4 substrates, including the antifungal Voriconazole and certain immunosuppressants like Ciclosporin.

Additionally, Flucloxacillin is involved in competition for renal tubular secretion pathways. Co-administration with Probenecid delays the renal excretion of Flucloxacillin, resulting in increased and prolonged plasma concentrations of Revistar. This same competitive mechanism exists with Methotrexate, which can lead to a risk of increased Methotrexate toxicity due to elevated serum levels.


Pharmacodynamic and Administration Constraints

A pharmacodynamic interaction is documented with Paracetamol (Acetaminophen), where co-treatment has been associated with the potential risk of High Anion Gap Metabolic Acidosis (HAGMA). This risk is specifically highlighted in official labeling for patients with underlying factors such as severe renal impairment, sepsis, or malnutrition.

Flucloxacillin can also affect the efficacy of other agents, including reports of reduced effectiveness for the anticoagulant Warfarin. Furthermore, co-administration is officially stated to render the Oral Typhoid Vaccine less effective.

For oral administration, food reduces the absorption (lowering AUC and Cmax) of Flucloxacillin. Therefore, official guidance establishes a mandatory administration timing rule requiring the medicine to be taken on an empty stomach (separated from meals by at least one to two hours).

Mechanism of Action

How Revistar Works


Irreversible Blockade of Bacterial Cell Wall Construction

Revistar (Flucloxacillin) functions as a highly specific, irreversible inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are essential for constructing the protective cell wall. The drug's beta-lactam structure covalently binds to and acylates the active site of the PBP transpeptidases. This molecular interaction immediately halts the crucial peptidoglycan cross-linking process. This disruption initiates a lethal physiological cascade, leading directly to the bactericidal effect and subsequent pathogen clearance.


Structural Defense Against Bacterial Enzymes

A key feature of the drug's mechanism is its intrinsic resistance to penicillinase (beta-lactamase) enzymes produced by many susceptible bacteria. The molecule's unique structural configuration physically defends its active beta-lactam core from hydrolytic deactivation. This specificity ensures the inhibitory mechanism remains functional against pathogens employing this common defense, thus allowing the structural inhibition and cell lysis cascade to proceed effectively.


Mechanism Constraint: Target Enzyme Modification

The mechanism is entirely dependent on the structural compatibility between the drug and the PBP target. In scenarios where bacteria possess genetically altered PBPs, such as in MRSA, the binding affinity is drastically reduced. This modification within the target enzyme domain limits the drug's effectiveness because the primary inhibitory cascade cannot be initiated, resulting in a mechanism failure against these specific resistant organisms.

Dosage and Administration Information

How to use Revistar — Official Administration Guidelines

The administration of Revistar (Flucloxacillin) is governed by specific instructions which define the approved delivery methods, dosing, and timing constraints.


Administration Scope

Feature Guideline (Strictly Label-Based)
Route of administration Primarily Oral (Capsules, Suspension) or Parenteral (Intravenous slow injection/infusion, Intramuscular), depending on the required systemic delivery.
Dosing schedule The Standard Adult Oral Dose is typically 250 mg to 500 mg. For severe systemic infections, the dose may be increased up to mathbf8 g daily in divided doses.
Timing in relation to meals Oral forms must be taken on an empty stomach to ensure optimal absorption, generally 30 to 60 minutes before a meal or two hours after.
Age-group administration rules Pediatric dosing is calculated by body weight and administered in divided doses. Severe Renal Impairment (CrCl < 10 mL/min): Requires a dose reduction or extended dosing interval.
Course Duration The course for acute infections typically lasts 7 to 14 days. Extended, long-term treatment lasting several months is required for deep-seated conditions, such as osteomyelitis.

Connection to the Official Use Protocol

The instructions establish a structured protocol that defines the method, dosage, frequency, and duration for Revistar administration. This framework dictates that oral administration must be separated from meals and specifies the need for frequent dosing (typically four times a day) to maintain continuous systemic levels of the active ingredient. Standard protocols also outline mandatory dosage modifications for specific populations, such as those with severely compromised kidney function, thereby standardizing its use across clinical contexts.

Recent Clinical Evidence

Revistar: Recent Clinical Evidence


Research Evidence for Skin and Soft Tissue Infections

Clinical research exploring the use of Revistar in conditions like cellulitis and abscesses includes Randomized Controlled Trials (RCTs) and large observational analyses. These studies were designed to compare treatment approaches and assess outcomes across broad patient groups with common localized infections. Researchers in these studies examined outcomes related to physical discomfort and the outcomes describing episodic or acute changes in patient status at the end of treatment. Findings describe observed patterns in the study populations, and these reported measurements contribute to the broader evidence landscape.

Research Evidence for Systemic and Deep-Seated Infections

Revistar was evaluated in more severe or complicated infections, such as bloodstream infections (septicemia), infective endocarditis, and bone infections (osteomyelitis). The research base relies predominantly on large prospective and retrospective observational cohort studies which monitored outcomes in real-world patient groups. These studies examined outcomes related to systemic or functional imbalance, including outcomes monitoring physiological strain or stress at defined time intervals (e.g., 30 or 90 days) and measurements of infection persistence or relapse over the following year.

Evidence on Long-Term Outcomes, Patient Populations, and Limitations

For deep-seated conditions, research examined outcomes over much longer periods, sometimes extending up to 12 months or more. These findings contribute to understanding symptom patterns, but long-term effects are not fully established beyond the observed follow-up periods. Revistar was studied for use in a variety of patient groups, including older adults and those with other health conditions (comorbidities). The results apply only to the populations studied, and outcomes may vary. What is still uncertain relates primarily to ongoing optimization and comparative data, as comparative evidence remains limited in the form of large, modern RCTs against alternative antibiotics for many complex infections.

Key Studies & References

  1. National Library of Medicine - Flucloxacillin Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Revistar (FAQ)


Q: How quickly should I expect Revistar to start working?

A: Patients commonly report or observe an improvement in symptoms within a few days of starting the Revistar course, as the medicine works quickly to target the infection. If there is no improvement or if symptoms worsen after a few days, it is recommended to consult with a healthcare provider.


Q: Is it safe to drink alcohol in moderation while on Revistar?

A: Regulatory guidance suggests that consuming alcohol in moderation is generally permissible while undergoing treatment with this medicine. Any potential side effects may be exacerbated by consuming alcohol. Patients should review their alcohol consumption with a healthcare professional.


Q: Will Revistar interact with common over-the-counter pain relievers?

A: Official labeling highlights that co-treatment with Paracetamol (Acetaminophen) has been associated with a potential risk of a serious blood condition called High Anion Gap Metabolic Acidosis (HAGMA). This risk is primarily noted for patients with underlying risk factors like kidney problems. Patients should discuss taking Revistar concurrently with any over-the-counter medication with a healthcare provider.


Q: What are the signs that Revistar is actually working for me?

A: Signs that may indicate Revistar is working include a reduction in symptoms related to the bacterial infection, such as decreased pain, swelling, fever, or other localized signs. The rate of improvement can depend on the type and severity of the infection.


Q: Is Revistar a maintenance medication that you take for a long time?

A: Revistar is typically prescribed for a short course, generally 7 to 14 days, to treat acute infections. However, official information notes that an extended, long-term course lasting several months may be necessary for deep-seated or serious conditions like bone infections (osteomyelitis).


Q: How long does the effect of a Revistar dose usually last?

A: Official information indicates that the drug has a short half-life, meaning it is quickly processed and eliminated by the body. Because of this, doses are typically spaced out frequently throughout the day to ensure a continuous therapeutic level of the medicine in the body.


Q: Can I use common cold or flu medicines while taking Revistar?

A: Many common cold and flu medicines contain Paracetamol, which official warnings state has a potential interaction risk with this medicine. Given the risk, patients are advised to review the ingredients of cold/flu products and discuss any potential combination with a healthcare professional.


Q: Are there different strengths of Revistar, and why would a doctor choose one over another?

A: Yes, Revistar is typically supplied in different strengths, such as 250 mg and 500 mg capsules. Official labeling states that the dose level is determined by clinical factors, including the type and severity of the bacterial infection being treated.


Q: Can I crush or split Revistar tablets if I have trouble swallowing pills?

A: Official patient information indicates that the oral capsules are generally intended to be swallowed whole with a full glass of water. Modifying the capsule by chewing or breaking it is not recommended, as this may lead to discomfort or irritation of the throat and esophagus.


Q: Why do people sometimes say Revistar makes them feel 'foggy' or less sharp?

A: Reported side effects have rarely included central nervous system (CNS) effects, such as dizziness. In very rare cases, convulsions (seizures) have occurred, most often in patients with pre-existing conditions like severely impaired kidney function or those receiving very high doses.


Q: What are the most common mild side effects reported for Revistar?

A: The most common side effects reported in regulatory documents, affecting up to 1 in 10 people, include mild gastrointestinal issues. These often involve diarrhoea, an upset stomach, feeling sick (nausea), and heartburn. These effects are usually mild and tend to wear off within a few days of starting treatment.


Q: Can Revistar affect my sleep patterns, like insomnia or drowsiness?

A: Official regulatory documents have reported central nervous system side effects, including dizziness and headache. While not directly listed as affecting sleep, these disturbances are rare and could potentially impact rest or alertness.


Q: Is it normal to feel a bit nauseous when first starting Revistar?

A: Yes, official safety information lists nausea (feeling sick) as a common side effect. This type of reaction is frequently experienced by patients beginning treatment and is usually temporary, subsiding after the first few days.


Q: Can Revistar affect blood pressure or heart rate?

A: In very rare cases, the medicine has been associated with conditions that could potentially affect the cardiovascular system, such as inflammation of the kidney (nephritis). In rare instances and typically with very high doses, the drug may lead to low potassium levels (hypokalaemia), which can impact muscle function.


Q: What happens if I accidentally miss a dose of Revistar?

A: Official patient information describes a protocol for missed doses: if a dose is forgotten, it can be taken as soon as the oversight is realized, unless it is nearly time for the next scheduled dose. Patients are advised against taking two doses simultaneously to make up for a missed dose.


Q: Is there a generic version of Revistar available yet?

A: Yes, the active ingredient in Revistar, which is Flucloxacillin, is widely available internationally. It is marketed under various brand names and is also produced as a generic medicine by multiple pharmaceutical manufacturers.


Q: Has Revistar been studied in people with kidney or liver issues?

A: Official guidance documents require specific considerations for these populations. Dose adjustment or extended dosing intervals are required for patients with severe kidney impairment. Furthermore, monitoring of liver function is advised, especially during prolonged treatment.


Q: Are there any specific foods I should avoid while on Revistar?

A: The most important instruction regarding food is the mandatory administration timing rule. Official documents require that the oral form of Revistar be taken on an empty stomach, separated from any meal by at least one to two hours, to ensure the medicine is properly absorbed by the body.


Q: Is Revistar approved for use in teenagers or adolescents?

A: Yes, the official dosing information includes specific instructions for all age groups, including children and adolescents. The appropriate dose is determined by the healthcare provider based on the patient's age and body weight.


Q: Can Revistar interact with herbal supplements like St. John's Wort?

A: Most herbal remedies and supplements are not tested for safety with prescription drugs in the same manner as pharmaceutical interactions. Regulatory sources suggest that patients discuss the use of herbal remedies or supplements with a healthcare professional before combining them with this medicine.


Q: What are some less common but more serious side effects of Revistar to watch out for?

A: Serious adverse reactions are rare, occurring in less than 1 in 10,000 people. These include potentially severe liver damage, such as hepatitis and cholestatic jaundice, as well as severe skin reactions. Symptoms like yellowing of the skin or eyes (jaundice) require immediate consultation with a healthcare professional.


Q: Are there any specific warnings for women who are pregnant or breastfeeding regarding Revistar?

A: Official information advises that the medicine should only be used during pregnancy or while breastfeeding if a healthcare professional determines that the potential benefit to the mother outweighs any potential risk to the baby. It is also noted that the drug is known to pass into breast milk.


Q: Is Revistar considered a controlled substance?

A: No, Revistar (Flucloxacillin) is not classified as a controlled substance. It is regulated as a Prescription-Only Medicine (POM) in most countries, meaning it requires a prescription from an authorized practitioner.


Q: How long does it take for any side effects of Revistar to typically go away?

A: Common, mild side effects like nausea or diarrhoea are generally transient and are expected to resolve after the first few days of treatment. Side effects like liver toxicity are rare but may persist for a longer period and require ongoing medical supervision.


Q: Is there a specific time of day best for taking Revistar?

A: Official patient leaflets recommend that doses be spaced out evenly throughout the day to ensure that the blood levels of the medicine remain consistent. Due to the need for continuous blood levels, doses are often spaced evenly across the day.


Q: Will taking Revistar require regular blood tests or monitoring?

A: Yes, official guidance advises that regular monitoring of liver function may be necessary, particularly if the treatment course is prolonged. Furthermore, patients receiving high doses may require regular measurements of their blood potassium levels.


Q: Does the effectiveness of Revistar change depending on diet?

A: The effectiveness of the oral form of Revistar is known to be affected by food, which significantly reduces its absorption. For this reason, official instructions mandate taking the medicine on an empty stomach. No other general dietary changes are specifically noted.


Q: Is Revistar known to cause skin rashes or sensitivity to the sun?

A: Official safety documents indicate that the drug can cause various types of skin rashes, including erythematous maculopapular rashes and hives (urticaria). While rare, severe cutaneous adverse reactions have also been reported.

How should Revistar be stored and disposed of?

The required storage conditions for Revistar (Flucloxacillin) differ based on the dosage form and are explicitly defined by regulatory agencies.

  • Unmixed Powder and Capsules: The dry product must be kept in the original container, stored in a dry place, and protected from light. Storage temperatures are typically specified as being below 25 C or 30 C.
  • Reconstituted Oral Solution: Once mixed, the liquid solution has a limited stability and must be stored under refrigeration, generally at 2 C to 8 C, and is typically stable for only 7 days before it must be discarded.

Official Disposal and Safety

The medicine must be kept out of the sight and reach of children. Unused or expired product should not be disposed of via wastewater or household trash. Disposal must be performed according to local requirements, often involving returning it to a pharmacy or using a community drug take-back program to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Revistar found in:

A-Z Index: